Navigation Links
New Finding Suggests Safe Surgical Margins When Removing Breast Cancers
Date:10/21/2010

THURSDAY, Oct. 21 (HealthDay News) -- A new study suggests that in women undergoing breast-conserving surgery, removing at least 2 millimeters of healthy tissue in addition to a cancerous breast tumor is enough to lower the risk of residual cancer.

Surgeons disagree about how much of a "free margin" around a tumor is ideal, according to the study, which appears online in the November issue of IJCP, the International Journal of Clinical Practice. In the United Kingdom, about two-thirds of surgeons surveyed said they prefer a margin of 2 millimeters or more, while nearly a quarter favor removing only 1 millimeter.

"The issue is that whenever you take a lump out of someone's breast, you want to have some normal tissue around the entire malignancy. That's how the surgeon can make the statement that 'I think I got the whole thing,'" said Dr. Otis Brawley, chief medical officer of the American Cancer Society.

Surgeons often perform a procedure again if they don't think the margins are large enough, Brawley said.

In the new study, researchers from Good Hope Hospital in West Midland, U.K., examined the medical records of 303 breast cancer patients undergoing breast conservation therapy to remove a cancerous lump. They found that 44 percent underwent follow-up surgery because the margins around the tumors were less than 5 millimeters and considered too small. Upon examination of the excised tissues, however, only about 2 percent of those with margins of 2 millimeters or more showed signs of residual cancer.

This meant that with a free margin of 2 millimeters or more, 98 percent of the patients showed no signs of residual cancer, the researchers said.

In addition, they found that the amount of residual disease decreased as the margin increased: 35.3 percent of the women who underwent surgery for invasive breast cancer had residual cancer with no margin, compared to 2.4 percent with a margin of more than 2 millimeters.

"Our results clearly show a relationship between the width of the free margin and the likelihood of finding residual disease at further surgery," the researchers wrote. "To minimize the risk of residual disease, we would recommend aiming for a free margin from invasive tumor of 2 millimeters."

However, the study authors noted that the findings did not apply to women with a precancerous condition known as ductal carcinoma in situ (DCIS). One-third of the patients with DCIS had residual disease even with a free margin up to 5 millimeters. "The equivalent free margin for DCIS remains unknown," they wrote.

Brawley said surgeons may someday embrace 2-millimeter margins around malignant tumors and perform fewer follow-up surgeries as a result. "But it'll be a while before people gravitate to it," he said.

More information

The U.S. National Library of Medicine has more on breast cancer.

-- Randy Dotinga

SOURCE: International Journal of Clinical Practice, Oct. 20, 2010; Otis Brawley, M.D., chief medical officer, American Cancer Society; press release, Oct. 18,


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. $4.37 million NCI grant accelerates recent laboratory finding in Ewings sarcoma
2. Encouraging findings suggest new avenues for treating liver disease in overweight Americans
3. Latest Findings Back Mammograms for Women in Their 40s
4. National committee releases findings on transforming and improving the nursing profession
5. Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders
6. Scientists closer to finding what causes the birth of a fat cell
7. New findings further clarify breast cancer risk with hormone therapy
8. Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts
9. U. Iowa biologists publish findings on cell interactions
10. Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course
11. Tel Aviv University Fertility Research Confirms New York Center's DHEA Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Finding Suggests Safe Surgical Margins When Removing Breast Cancers
(Date:5/2/2016)... and Shelton, CT (PRWEB) , ... May 02, 2016 , ... ... President and Owner of New England Low Vision and Blindness (NELV&B) , announces ... add more flexibility and convenience for people with vision impairments to get assessments, hands-on ...
(Date:5/1/2016)... ... May 01, 2016 , ... ... that gives new mothers a better understanding of what to expect after they ... Adjusting to baby postpartum, · The blues and depression, · Breastfeeding beyond postpartum ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published ... her enthusiasm for Botox and lip injections, which she underwent in order to feel ... Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... BASEL , Schweiz, April 27, 2016 ... des Sachs CEO Forums in Zürich ... Phase-II-Studie ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung ... (CI) eingesetzt wurde, bekannt. Für die umfassende ... Deutschland und Frankreich angeworben. STR001 wird während ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: